Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N., Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Tsang, Garson, West, Brian L., Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam Y. J., Artis, Dean R., Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D'Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S., Lee, Richard J., Grippo, Joseph, Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., Chapman, Paul B., Flaherty, Keith T., Xu, Xiaowei, Nathanson, Katherine L., Nolop, Keith
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
https://www.ncbi.nlm.nih.gov/pubmed/20823850
http://dx.doi.org/10.1038/nature09454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
https://www.ncbi.nlm.nih.gov/pubmed/20823850
http://dx.doi.org/10.1038/nature09454

Ejemplares similares